HIV infection at screening
participation in previous or concurrent HIV vaccine trials
lactating, pregnant or planning pregnancy
renal function impairment (serum creatinine >1.5 mg/dl), Fanconi syndrome
abnormal liver function tests (AST/ALT > 43 U/L), liver disease, viral hepatitis, hepatitis B virus (HBV) infection
serum phosphorus <2.2mg/dl, osteoporosis
known sensitivity to components of the Truvada® formulation
any immunosuppressive treatment, such as systemic corticosteroids
assumption of medication that interacts with Truvada®
high likelihood of poor adherence to PREP and clinic attendance
any condition that in the opinion of the attending physician could endanger the health of the participant or render her unsuitable to participate in the trial

NCT02593409_exc_T1
Condition
HIV infection
NCT02593409_exc_T4
Condition
renal function impairment
NCT02593409_exc_T5
Measurement
serum creatinine
NCT02593409_exc_T6
Value
>1.5 mg/dl
NCT02593409_exc_T7
Condition
Fanconi syndrome
NCT02593409_exc_T8
Measurement
liver function tests
NCT02593409_exc_T9
Value
abnormal
NCT02593409_exc_T10
Measurement
AST
NCT02593409_exc_T11
Measurement
ALT
NCT02593409_exc_T12
Value
> 43 U/L
NCT02593409_exc_T13
Scope
AST/ALT
NCT02593409_exc_T14
Condition
liver disease
NCT02593409_exc_T15
Condition
viral hepatitis
NCT02593409_exc_T16
Condition
hepatitis B virus (HBV) infection
NCT02593409_exc_T17
Measurement
serum phosphorus
NCT02593409_exc_T18
Value
<2.2mg/dl
NCT02593409_exc_T19
Condition
osteoporosis
NCT02593409_exc_T20
Condition
sensitivity
NCT02593409_exc_T21
Drug
Truvada
NCT02593409_exc_T22
Procedure
immunosuppressive treatment
NCT02593409_exc_T23
Drug
systemic corticosteroids